Openbookopenbook
Equity
Medpace Holdings Inc(MEDP)
USD --+0.00%
Reward66High
Risk27Low
📊75%Data
Strong 18% profit margin · Revenue growing 32% YoY
MEDP
+0.0 · +0.00%
USD · NASDAQ
Medpace Holdings Inc | Healthcare
Quality Compounder
Market Cap:12.43Bn
ℹ️
Reward Rating
66
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
27
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MEDP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $486.92.

What is Medpace Holdings Inc?

provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

MEDP · Verdict

Solid reward · low risk

MEDP stands out on cash flow and growth, but watch the valuation signal.

Based on 88% data coverage

MEDP · Verdict

What’s working & what to watch

Strengths 4

  • Cash flow94/100

    27% free-cash-flow margin

  • Growth84/100

    Rev +20.1% CAGR · earnings +22.5%

  • Balance sheet81/100

    Current ratio 0.74

  • Profitability75/100

    18% net margin · 70% ROE

Watchouts 2

  • Valuation35/100

    P/E 36.2× · PEG 4.14

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Medpace Holdings Inc?

provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 12.43B, and a P/E ratio of 28.7x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (66)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap12.43B
P/E Ratio28.6514
Dividend YieldN/A
52 Week High628.9155
52 Week Low250.05
Last AnnualDecember
IPO Date8/11/2016
IncorporatedUSA
Shares Outstanding28M
No. of Employees6,200
IndustryDiagnostics & Research
ExchangeNASDAQ
Beta1.402
CurrencyUSD
Websitewww.medpace.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.